Form 4: Herbalife COO Troy Hicks Granted 33,301 SARs

Sentiment:

Executive Equity Grant


Herbalife's Chief Operating Officer, Troy Hicks, was granted 33,301 Stock Appreciation Rights with an exercise price of $10.51.

Summary

  • Troy Hicks, Chief Operating Officer of Herbalife Ltd. (HLF), was granted 33,301 Stock Appreciation Rights (SARs).
  • The SARs have an exercise price of $10.51 per share.
  • The grant date for these SARs was February 25, 2026.
  • These SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029.
  • Vesting is contingent upon continued service through each respective date.
  • The SARs were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.
  • The expiration date for these SARs is February 25, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

  • The grant of Stock Appreciation Rights to the Chief Operating Officer aligns management's incentives with shareholder value creation, as SARs only gain value if the stock price increases above the exercise price of $10.51.
  • The long-term vesting schedule over three years encourages executive retention and sustained performance.

Negatives

  • The grant of SARs could lead to potential dilution if exercised, although SARs are typically settled in cash or net shares, limiting direct share count increase.
  • The value of the SARs is entirely dependent on future stock price appreciation, introducing a performance-based risk for the executive.

Future Outlook

The vesting schedule for the SARs extends through February 2029, indicating a long-term incentive structure tied to the company's future performance and the executive's continued service.

Industry Context

StockSavvy.ai notes that granting equity-based incentives like SARs to key executives is a standard practice across various industries, particularly in consumer goods and direct selling, to align management's interests with long-term shareholder value. This practice is common for companies seeking to retain talent and motivate performance in competitive markets.

Comparison to Industry Standards

  • The grant of 33,301 SARs to a Chief Operating Officer is within the typical range for executive compensation packages in companies of similar market capitalization and industry, such as Nu Skin Enterprises (NUS) or USANA Health Sciences (USNA), which also utilize performance-based equity awards to incentivize their leadership.
  • The exercise price of $10.51, being the market price at the time of grant, is standard for SARs and options, ensuring that the executive benefits only from future stock price appreciation.
  • A three-year vesting schedule with annual increments is a common structure designed to promote executive retention and long-term strategic focus, comparable to practices observed at companies like GNC Holdings or Vitamin Shoppe (now part of Franchise Group).

Stakeholder Impact

  • Shareholders: The grant aligns the COO's financial interests with share price appreciation, potentially benefiting shareholders if the company performs well.
  • Employees: This grant is specific to a key executive and does not directly impact the broader employee base, though it signals the company's approach to executive incentives.

Next Steps

  • The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to Troy Hicks' continued service.

Key Dates

DateDescription
02/25/2026Date of earliest transaction and grant date for Stock Appreciation Rights.
02/27/2026Signature date of the reporting person's attorney-in-fact.
02/25/2027First one-third increment vesting date for the SARs.
02/25/2028Second one-third increment vesting date for the SARs.
02/25/2029Third and final one-third increment vesting date for the SARs.
02/25/2036Expiration date of the Stock Appreciation Rights.

Recommendation

hold

This Form 4 filing details a routine executive compensation event (grant of SARs) and does not contain information that would fundamentally alter the investment thesis for Herbalife. While it aligns executive incentives, it's a standard practice and not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' and monitor broader company performance and market trends.

Keywords

Herbalife, HLF, Stock Appreciation Rights, SARs, Executive Compensation, Troy Hicks, Chief Operating Officer, Equity Grant, Incentive Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.